Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Late-stage clinical development of Chikungunya vaccines in endemic countries (CHIKV) and Controlled Human Infection Models for SARS-CoV2 and other beta coronaviruses (CHIM).

Descrizione del progetto

Sviluppo clinico di vaccini contro il virus Chikungunya

Il virus Chikungunya (CHIKV) è un agente patogeno trasmesso dalle zanzare che causa febbre e dolori articolari debilitanti, per il quale attualmente non esistono trattamenti antivirali specifici. Sebbene diversi vaccini contro il CHIKV abbiano raggiunto la fase precedente alla concessione dell’autorizzazione, sono necessari ulteriori studi per valutarne la sicurezza e l’efficacia a lungo termine. Il progetto CHIKVAX_CHIM, finanziato dall’UE, si propone di sostenere lo sviluppo clinico di vaccini contro il CHIKV nell’ambito di sperimentazioni cliniche di fase IV concentrandosi su popolazioni vulnerabili quali bambini, individui immunosoppressi e donne in gravidanza. L’iniziativa messa in atto dal progetto fa parte di un accordo più ampio tra la Coalizione per l’innovazione in materia di preparazione alle epidemie (CEPI) e l’Unione europea inteso a sviluppare contromisure mediche per le minacce epidemiche emergenti. Inoltre, CHIKVAX_CHIM consentirà di far progredire la ricerca sull’immunità mucosale indotta dai vaccini e stabilirà una rete globale di esperti sugli studi delle infezioni umane in ambienti controllati.

Obiettivo

A Framework Partnership Agreement (FPA) between the Coalition for Epidemic Preparedness Innovations (CEPI) and the European Union (EU) was signed in April 2019, to finance and coordinate the development of new medical countermeasures to prevent and contain infectious disease epidemics, which are of particular concern to low- and middle-income countries. As part of the FPA, a call for proposals (CfP) was launched jointly with the EU and supported the preclinical development of Rift Valley Fever Virus vaccines and the late-stage development of Chikungunya virus vaccines (CHIKV). While previous funding has led to the development of pre-licensure CHIK vaccines, in this current application we like to further advance our CHIK vaccine programme, and support CHIK vaccines that are near or have achieved regulatory licensure by supporting their clinical development into phase IV clinical trials to increase our understanding of the long-term safety, durability of protection, and effectiveness against virologically confirmed disease. Furthermore, we would like to expand the use indication by supporting clinical trials in vulnerable populations, including children, immunosuppressed and pregnant women. 

As part of this grant application, we also like to launch a CfP on Controlled Human Infection Models (CHIM). The overall objective of the CHIM proposal is to support research projects that increase knowledge in vaccine-induced mucosal immunity and advance the development of transmission-blocking vaccines against coronaviruses and other potential respiratory viral threats. The expected outcome of this CfP is to create a global network of experts conducting CHIM at a high level of consistency and reliability.

This current grant application seeks to leverage €70M from Horizon Europe, which will be supplemented with €30M from CEPI making a pool of €100M. Awards will have a 36–48-month duration and will be administered by the CEPI secretariat.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-COFUND - HORIZON Programme Cofund Actions

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-HLTH-2022-CEPI-15-IBA

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS
Contributo netto dell'UE
€ 70 000 000,00
Indirizzo
SKOYEN ATRIUM ASKEKROKEN 11
0277 Oslo
Norvegia
Regione
Norge Oslo og Viken Oslo
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 100 000 000,00